In short
This article discusses the ongoing clinical trials of STC-1010, an innovative immunotherapy drug being tested for patients with advanced or metastatic colorectal cancer. The BreAK CRC trial is a Phase I/IIA study aimed at evaluating the safety, efficacy, and optimal dosing of STC-1010 when combined with standard-of-care treatments. This research offers hope for patients with difficult-to-treat forms of colorectal cancer, particularly those who have not responded to previous therapies.
At a glance
- Study Name
- BreAK CRC trial (BreAK for Brenus Anti-cancer)
- Drug Tested
- STC-1010 (immunotherapy)
- Target Condition
- Unresectable locally advanced or metastatic colorectal cancer
- Study Design
- Open-label, multicenter, Phase I/IIA trial
- Primary Objectives
- Safety profile, optimal dose determination, clinical efficacy
- Key Eligibility
- Adults 18-75, specific tumor characteristics (MSS or MSI-H)
- Treatment Combination
- STC-1010 with mFOLFOX6 + bevacizumab, followed by maintenance therapy
- Primary Endpoint
- Progression-free survival rate at 12 months (Phase IIA)
What is STC-1010?
STC-1010, also known as Stimulated Tumor Cells-1010, is a new type of cancer treatment called immunotherapy. It is currently being studied as a potential treatment for advanced colorectal cancer. STC-1010 is made up of specially prepared cells that come from colorectal cancer tumors.
How does STC-1010 work?
STC-1010 works by stimulating your body's immune system to fight cancer cells. It contains six different types of cancer cells that have been modified in a laboratory: HCT116-A and HCT116-B HT-29-A and HT-29-B LOVO-A and LOVO-B These modified cancer cells are designed to activate your immune system and help it recognize and attack similar cancer cells in your body.
What conditions does STC-1010 treat?
STC-1010 is being studied for the treatment of unresectable locally advanced or metastatic colorectal cancer. This means: Unresectable: The cancer cannot be completely removed with surgery Locally advanced: The cancer has spread from where it started to nearby tissue or lymph nodes Metastatic: The cancer has spread to other parts of the body Specifically, it is being tested in patients with colorectal cancer that is either stage IIIC (T4b) or stage IV.
Current research on STC-1010
STC-1010 is currently being studied in a clinical trial called the BreAK CRC trial. This trial has two main parts: Phase I: This part aims to determine the safety of STC-1010 and find the right dose to use. Phase IIA: This part will test how well STC-1010 works in treating colorectal cancer. The study is testing STC-1010 in combination with other cancer treatments, including chemotherapy (like FOLFOX) and other targeted therapies (like bevacizumab).
Who may be eligible for STC-1010 treatment?
The clinical trial is looking at two main groups of patients: Patients with MSS (microsatellite stable) colorectal cancer who haven't had treatment before. Patients with MSI-H (microsatellite instability-high) colorectal cancer, including those with Lynch syndrome, whose cancer has gotten worse after at least 4 months of immunotherapy. To be eligible, patients must: Be between 18 and 75 years old Have a life expectancy of more than 3 months Have cancer that can be measured Have good overall health and organ function There are also several factors that might make someone ineligible for the trial, such as having certain other medical conditions or having had specific treatments recently.
Potential side effects and safety considerations
As STC-1010 is still in the early stages of testing, all of its potential side effects are not yet known. The clinical trial is designed to carefully monitor patients for any side effects or safety concerns. Some general considerations for patients receiving immunotherapy treatments like STC-1010 include: Immune-related side effects, which can affect various parts of the body Potential interactions with other medications, especially those that affect the immune system The need for close monitoring by healthcare professionals throughout treatment It's important to note that STC-1010 is still an experimental treatment and is not yet approved for general use. Patients considering participating in the clinical trial should discuss the potential risks and benefits thoroughly with their healthcare team.